Skip to main content
Explore URMC

Acute Myeloid Leukemia (AML): Crenolanib Versus Midostaurin in Newly Diagnosed Subjects With FLT3 Mutated AML

Research Question:
Does the drug Crenolanib help patients with acute myeloid leukemia survive?

Basic Study Information

This purpose of this study is to compare the efficacy of crenolanib with midostaurin administered following induction chemotherapy and consolidation therapy on event-free survival in newly diagnosed acute myeloid leukemia subjects with FLT3 mutation.

Study Reference #: ILEU17106

Lead Researcher (Principal Investigator)

Lead Researcher: Jane Liesveld, MD

Study Contact Information

Study Coordinator: Haley Misch
Phone: (585) 275-9485

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search